digoxin and Carcinoma--Squamous-Cell

The cardiac effects of hypercalcaemia are usually manifest as a shortening of the QT-interval. Hypercalcaemia is infrequently associated with a clinically manifest arrhythmia. However, concomitant therapy with digoxin or underlying cardiac disease can potentiate the arrhythmogenic effects of hypercalcaemia, leading to a symptomatic rhythm disorder. We describe a symptomatic arrhythmia, which developed in a patient with hypercalcaemia secondary to squamous cell carcinoma of the bronchus. The patient was on digoxin therapy at the time. The arrhythmia did not recur after discontinuation of digoxin therapy and correction of the hypercalcaemia. Because of its effect on cardiac conduction, hypercalcaemia should be considered in the evaluation of any patient with an unexplained bradyarrhythmia. Conversely, patients with hypercalcaemia should discontinue digoxin therapy and be evaluated for the presence of rhythm disorders while receiving appropriate treatment for hypercalcaemia.

Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Bradycardia; Bronchial Neoplasms; Carcinoma, Squamous Cell; Contraindications; Digoxin; Female; Humans; Hypercalcemia

The present study evaluated the expression of α1 and β1 Na,K-ATPase, as well as the effects of digoxin (DGX) on oral squamous cell carcinomas (OSCCs).. Immunohistochemical expression of α1 and β1 Na,K-ATPase were evaluated in 60 patients who underwent treatment at the São João de Deus Hospital. SCC-25 viability was assessed by the colorimetric assay. Chi-square or Fisher's exact tests were used to analyze the association of α1 and β1 Na,K-ATPase expression with the variables.. Immunoexpression of α1 and β1 Na,K-ATPase were observed in 28% and 55% of the tumors, however these proteins were not significant prognostic factors. Tobacco was significantly associated with α1 expression. SCC-25 viability decreased significantly after treatment with 1 μM DGX at 24 h.. The smoking status of OSCC patients was significantly associated with α1 expression and DGX affected the SCC-25 viability in a dose- and duration-dependent manner.

Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Digoxin; Enzyme Inhibitors; Humans; Mouth Neoplasms; Neoplasm Grading; Neoplasm Staging; Protein Subunits; Risk Factors; Sodium-Potassium-Exchanging ATPase

Topics: Administration, Oral; Adult; Biological Availability; Carcinoma, Squamous Cell; Digoxin; Female; Heart Failure; Humans; Injections, Intramuscular; Intestinal Absorption; Malabsorption Syndromes; Radiotherapy; Solutions; Tablets; Uterine Cervical Neoplasms